Stockscreener 앱 받기
20.21
4.40%
-0.93
시장 영업 전:
20.53
0.32
+1.58%
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
UroGen Pharma at Guggenheim Summit: Strategic Advances in Biotech By Investing.com - Investing.com South Africa
Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 7,479 Shares - MarketBeat
Market Sentiment Around Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st
(URGN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
UroGen Pharma CMO Schoenberg sells $145k in shares - Investing.com
UroGen Pharma CMO Schoenberg sells $145k in shares By Investing.com - Investing.com South Africa
Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 7,373 Shares - MarketBeat
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit - Caledonian Record
Urogen Pharma (NASDAQ:URGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Privium Fund Management B.V. Increases Stock Position in Urogen Pharma $URGN - MarketBeat
Update Recap: Is now the right time to enter UroGen Pharma LtdWeekly Risk Report & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Bull Run: Can UroGen Pharma Ltd deliver consistent dividendsJuly 2025 Spike Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Responsive Playbooks and the URGN Inflection - Stock Traders Daily
Dividend Watch: Is now the right time to enter UroGen Pharma LtdJuly 2025 Setups & Growth Oriented Trading Recommendations - baoquankhu1.vn
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA - GuruFocus
URGN: Analyst Jason Kolbert Maintains 'Buy' Rating with $33 Pric - GuruFocus
Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - MarketBeat
UroGen Pharma Ltd. (URGN) Stock Analysis: Investors Eye 83% Upside Amid Biotech Innovations - DirectorsTalk Interviews
Harel Insurance Investments & Financial Services Ltd. Trims Holdings in Urogen Pharma $URGN - MarketBeat
UroGen drops 20% as FDA releases docs in advance of AdCom meeting - MSN
JELMYTO shows promise in long-term cancer treatment study - MSN
Understanding the Setup: (URGN) and Scalable Risk - Stock Traders Daily
Technical Analysis: Is UroGen Pharma Ltd stock affected by interest rate hikesWeekly Trade Report & Weekly Top Stock Performers List - Bộ Nội Vụ
Urogen Pharma (NASDAQ:URGN) Stock Price Down 6.7%Here's What Happened - MarketBeat
Aug Shorts: How interest rate cuts could boost UroGen Pharma Ltd stockQuarterly Portfolio Report & Technical Pattern Based Signals - Bộ Nội Vụ
Momentum Shift: How interest rate cuts could boost UroGen Pharma Ltd stock2025 Performance Recap & Risk Controlled Daily Trade Plans - Bộ Nội Vụ
Assessing UroGen Pharma (URGN) Valuation After ZUSDURI Secures Permanent J Code - simplywall.st
Is UroGen Pharma Ltd stock ready for breakoutMarket Weekly Review & Accurate Buy Signal Notifications - Bộ Nội Vụ
Block Trades: Will UroGen Pharma Ltd stock benefit from infrastructure spending2025 Short Interest & Step-by-Step Swing Trade Plans - Bộ Nội Vụ
Why UroGen Pharma Ltd. stock appeals to analystsQuarterly Market Summary & Safe Entry Zone Identification - Улправда
Urogen Pharma (NASDAQ:URGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Will UroGen Pharma Ltd. stock benefit from infrastructure spendingChart Signals & Verified Swing Trading Watchlists - Улправда
Why UroGen Pharma Ltd. (UR8) stock attracts HNW investorsJuly 2025 Short Interest & Reliable Trade Execution Plans - ulpravda.ru
Is UroGen Pharma Ltd. stock oversold or undervalued2025 Market Outlook & High Win Rate Trade Tips - Улправда
What momentum indicators show for UroGen Pharma Ltd. stock2025 Key Highlights & Advanced Technical Analysis Signals - Улправда
Will UroGen Pharma Ltd. stock see insider buyingFundamental Strength Indicators & Free Unlock Rapid Growth Potential - Улправда
UroGen Pharma Ltd. (URGN) Stock Analysis: A Biotechnology Innovator with Over 52% Potential Upside - DirectorsTalk Interviews
Multiple Insiders Sold UroGen Pharma Shares Presenting Weak Signs For Investors - simplywall.st
How UroGen Pharma Ltd. (UR8) stock trades in high volatility2026 world cup usa national team round of 32 playmakers possession football expert forecast preview - Улправда
UroGen Pharma says permanent J Code for ZUSDURI now in effect - Yahoo Finance
Urogen Pharma (NASDAQ:URGN) Shares Down 6.5%What's Next? - MarketBeat
UroGen Pharma Ltd. Announces That Adult Patients Living with Recurrent Low-Grade Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) Now Have Improved Access to an Important Therapy - marketscreener.com
UroGen Pharma (URGN) Analyst Ratings Remain Steady with Buy Rati - GuruFocus
D. Boral Capital Reiterates "Buy" Rating for Urogen Pharma (NASDAQ:URGN) - MarketBeat
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy - GlobeNewswire
The Truth About UroGen Pharma (URGN): Is This Tiny Cancer Stock the Next Viral Game-Changer or a Tot - AD HOC NEWS
What analysts say about UroGen Pharma Ltd stockMarket Timing Techniques & Free High Velocity Capital Growth - earlytimes.in
The Technical Signals Behind (URGN) That Institutions Follow - Stock Traders Daily
URGN: Small-Cap Biotech On A Knife Edge As Traders Weigh Risk, Cash And Uro-Oncology Data - AD HOC NEWS
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally - AOL.com
Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term - Yahoo Finance
1.24%
0.19%
자본화:
|
볼륨(24시간):